# Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

> **NCT03797625** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 52 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** DDP
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT03797625
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797625, "Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03797625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*